Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Sigma Planning Corp

Sigma Planning Corp cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 58.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 5,213 shares of the biotechnology company’s stock after selling 7,192 shares during the quarter. Sigma Planning Corp’s holdings in Sarepta Therapeutics were worth $503,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Montag A & Associates Inc. acquired a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at $30,000. Cary Street Partners Investment Advisory LLC grew its position in Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 154 shares during the period. CWM LLC grew its position in Sarepta Therapeutics by 178.7% during the fourth quarter. CWM LLC now owns 577 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 370 shares during the period. Fifth Third Bancorp increased its stake in Sarepta Therapeutics by 1,215.8% during the fourth quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 924 shares during the last quarter. Finally, Hudson Capital Management LLC purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter worth about $206,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Price Performance

SRPT stock opened at $127.39 on Friday. The stock’s 50 day moving average is $126.22 and its two-hundred day moving average is $110.43. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $159.89. The company has a market capitalization of $11.96 billion, a PE ratio of -20.82 and a beta of 0.94. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.50. The business had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same quarter last year, the company earned ($1.24) earnings per share. Analysts predict that Sarepta Therapeutics, Inc. will post 2.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Ian Michael Estepan sold 1,200 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now owns 39,114 shares of the company’s stock, valued at $5,018,326.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the sale, the chief financial officer now owns 39,114 shares in the company, valued at $5,018,326.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Stephen Mayo sold 3,135 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $122.96, for a total value of $385,479.60. Following the transaction, the director now directly owns 6,621 shares in the company, valued at approximately $814,118.16. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock valued at $2,739,419 in the last ninety days. Corporate insiders own 7.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SRPT. Evercore ISI increased their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a research report on Tuesday, February 20th. Royal Bank of Canada increased their price objective on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Wedbush restated an “outperform” rating and set a $224.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Needham & Company LLC lowered their price target on Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating for the company in a report on Thursday, February 29th. Finally, UBS Group raised their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $158.38.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.